Bifogade filer
Warrants of series TO7 were exercised to approximately 96.4 percent and Prolight Diagnostics receives approximately SEK 12.6 million
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
Prolight Diagnostics AB (publ) (“Prolight” or the “Company”) announces today the outcome of the exercise of warrants of series TO7, which were issued during the fourth quarter of 2023 in the Company’s rights issue of units. In total, 104,802,373 warrants of series TO7 were exercised, corresponding to approximately 96.4 percent of the total number of outstanding warrants of series TO7, for subscription of 104,802,373 shares in the Company at a subscription price of SEK 0.12 per share. Prolight will receive approximately SEK 12.6 million before issue costs through the exercise of warrants of series TO7.
Background
The subscription period for exercise of the warrants of series TO7 took place from and including October 7, 2024, up to and including October 18, 2024. The subscription price per share for exercising the warrants of series TO7 was set to SEK 0.12.
In total, 104,802,373 warrants of series TO7 were exercised for subscription of 104,802,373 shares in the Company, meaning that approximately 96.4 percent of the total number of outstanding warrants of series TO7were exercised for subscription of new shares in Prolight.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Shares, share capital, and dilution
Through the exercise of the warrants of series TO7, the total number of shares in the Company will increase by 104,802,373, from 597,287,105 shares to 702,089,478 shares, and the share capital will increase with SEK 10,480,237.30, from SEK 59,728,710.50 to SEK 70,208,947.80. This corresponds to a dilution of approximately 14.9 percent of the total number of shares and 14.9 percent of the total number of votes in the Company. The dilution effect has been calculated as the number of additional shares and votes, respectively, in relation to the number of existing and additional shares and votes, respectively.
Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the exercise of the warrants of series TO7.